PD-1 like fire cooking oil Who is the next potential target?

On May 7, Cinda Biopharma and Lilly Pharmaceuticals jointly announced that the pD-1 immunosuppressant Damershu (Sindili monoantigen) combined with cadubolimono injections and platinum chemotherapy first-line treatment scaleNSCLC phase III pro-trial reached the main end pointPreviously, The listing application for the first-line treatment of non-phosphorus NSCLC by Dabershu United Lilly's Libitai and chemotherapy treatment has been accepted by the State Drug AdministrationCindy Li monoresist, an innovative PD-1 monoclonal antibody developed by Cinda Bio and Lilly, was approved in China at the end of 2018 for the treatment of recurrent/incurable classic Hodgkin's lymphoma, and was included in the new national health insurance catalog last November, becoming the only PD-1 inhibitor to enter the new national health insurance directorythe same day, following last week's listing of nasopharyngeal cancer indications, Junshi Bio's Tuyi (Triprien) for the treatment of previously treated local progressors or metastatic urinary disease (UC) patients have been accepted by the NMPA for the new indications17 years of The PD-1 in the abyss, in 19 years, such as japan rose, this year is the east and west, such as fire cooking oil, according to the 2020 Q1BMS and MSD financial results released, O drug 2020 Q1 q1 revenue of $1.766 billion, K drug revenue reached $3.284 billion, a surge of 45%, accounting for 31% of the pharmaceutical business revenuePD-1 has opened up the development pattern of multi-dimensional expansion, and joint therapy is a hot spot to exploreAmong them, in PD-1 research and development enterprises, China's local enterprises in the research market accounted for the majority of the share, MNC second(See Figure 1 for details)from the number of entries received by pharmaceutical companies at different stages of PD-1, Hengrui PD-1 performance is second to none, with BMS ranked firstOther such as Junshi Bio, Baiji Shenzhou, Cinda, MSD, etchave also taken the lead in the PD-1 market has also done a lot of investment, which is likely to be with the PD-1 "under the iceberg potential" to form a huge counter-productive, thereby further affecting the market(See figure II for details)PD-1 indications are also in the spotlight, and now cover more than 30 cancersIt is worth noting that there are also quite a few studies on stomach cancer and esophageal cancer with high prevalence of cancer in China, and a historic breakthrough is expected(See Figure 3 for details)the following chart compares the different focus of The Sino-US research targets, where the green proportion is most or even all, is the lack of the domestic market, even blank areas, these opportunities and challenges coexist in the field is expected to become the next "PD-1"?So the question is, how quickly can you spot potential targets? GBISOURCE database provides you with a combing of 45 popular targets including PD-1/PD-L1, EGFR, HER2 and other targets to help you better understand the research and development of targets and market information in China, and to provide an overview of the competitive landscape in this field (See Figure V for details)